|
|
Post by almannlives on Feb 2, 2017 10:15:19 GMT -5
I just don't see anything happening to stop the reverse split. Our only hope is if scripts rise dramatically in the next couple weeks. C'MON sales team number 3.
|
|
|
|
Post by jonny80s on Feb 2, 2017 11:39:54 GMT -5
An increase in sales numbers from the new sales team won't be seen for 3+ months. This will have no affect on the R/Split time line. There will be a split.
I'm not sure why everyone is so worried about it. We'll go from 500Mil to 50mil shares. The volume reduction will have a significant affect on options players. If they ever do find a way to sell the product the squeeze will be long and hard... .0001% chance of happening.
|
|
|
|
Post by sluggobear on Feb 2, 2017 14:30:12 GMT -5
I just don't see anything happening to stop the reverse split. Our only hope is if scripts rise dramatically in the next couple weeks. C'MON sales team number 3. In your title I expected you meant saving the company. Apparently you mean saving us from the reverse split? I don't think there's any saving from the RS. I am worried about saving the company and that only happens if Afrezza takes off. I've posted a few times now that the traditional approach is not working. Trying to get through the insurance/PA coverage & PBM barrier has kept this product out of the hands of thousands. Now I feel MannKind is desperate, as we are as investors, and should throw caution to the wind. Announce that they are going to give all T1Ds and PWDs nearly free insulin for a year to try. Announce that they are sticking it to the top 3 pharmas selling insulin, for taking advantage of PWDs in their insulin pricing conspiracy. I don't know what this will do to a relationship with insurance companies in the long run but if patients can get insulin very cheaply and not need insurance approval or go through step therapy or PAs etcetera, I believe the TRX number could really take off. |
|
|
|
Post by mytakeonit on Feb 2, 2017 15:01:29 GMT -5
From what I understand, the RS request will only be used if necessary and the request for it is just a way to cover MNKD's butt if it needs to. The RS doesn't change your equity value ... especially in this minimally churned stock. The primaries have held nicely and it is only the shorts trying to manipulate it.
What I heard on the CC was that although scripts haven't gone up ... sales are actually up from when Sanofi was handling it due to the increased size of scripts contents. I believe I remember up 25%? Anyway, volume today is slightly up but not excessive. Stock price is slightly down, but expected due to people reacting to RS being mentioned.
Sales team will be up and running and I feel fairly upbeat on the news.
|
|
|
|
Post by ptass on Feb 2, 2017 15:19:36 GMT -5
I don't see why the sec wont provide a 180 day extension and I'm disappointed Matt didn't mention anything about this on the call.
On another note, would someone clarify what Matt likely meant by delisting would be catastrophic to the operation of the business (or something to that effect). I assumed this meant raising capital at some point in the future by issuing stock but wasn't sure if there were other reasons.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 2, 2017 15:23:00 GMT -5
I don't see why the sec wont provide a 180 day extension and I'm disappointed Matt didn't mention anything about this on the call. On another note, would someone clarify what Matt likely meant by delisting would be catastrophic to the operation of the business (or something to that effect). I assumed this meant raising capital at some point in the future by issuing stock but wasn't sure if there were other reasons. possibly effect on debt issued ? debt holders may require continued Nasdaq listing? I dont know Plan to raise $$$ by diluting |
|
|
|
Post by careful2invest on Feb 2, 2017 15:33:36 GMT -5
From what I understand, the RS request will only be used if necessary and the request for it is just a way to cover MNKD's butt if it needs to. The RS doesn't change your equity value ... especially in this minimally churned stock. The primaries have held nicely and it is only the shorts trying to manipulate it. What I heard on the CC was that although scripts haven't gone up ... sales are actually up from when Sanofi was handling it due to the increased size of scripts contents. I believe I remember up 25%? Anyway, volume today is slightly up but not excessive. Stock price is slightly down, but expected due to people reacting to RS being mentioned. Sales team will be up and running and I feel fairly upbeat on the news. I think that the news of a quite probable (basically inevitable) reverse split that we learned last night is basically as bad as the actual Rs itself. The pps is down, as one would expect, but I think that the rs was/is somewhat priced in our current pps, and the hit on the stock price could have been much worse. Trying to stay positive, yet holding onto reality... GLTA TRUE LONGS! |
|
|
|
Post by promann on Feb 2, 2017 15:46:11 GMT -5
I don't see why the sec wont provide a 180 day extension and I'm disappointed Matt didn't mention anything about this on the call. On another note, would someone clarify what Matt likely meant by delisting would be catastrophic to the operation of the business (or something to that effect). I assumed this meant raising capital at some point in the future by issuing stock but wasn't sure if there were other reasons. I wonder if the Tase is also some how effected if we are delisted from Nasdaq ? anybody ? |
|
|
|
Post by agedhippie on Feb 2, 2017 19:25:03 GMT -5
I don't see why the sec wont provide a 180 day extension and I'm disappointed Matt didn't mention anything about this on the call. On another note, would someone clarify what Matt likely meant by delisting would be catastrophic to the operation of the business (or something to that effect). I assumed this meant raising capital at some point in the future by issuing stock but wasn't sure if there were other reasons. It's NASDAQ and not the SEC that would grant an extension. As the exchange operator NASDAQ controls the members - SEC regulates the actions of the greater market. Read the last 10Q. Delisting is covered in the Risks section, specifically Risks related to common stock, and tells you how bad it would be. |
|
|
|
Post by mnkdfann on Feb 2, 2017 19:40:37 GMT -5
I don't see why the sec wont provide a 180 day extension and I'm disappointed Matt didn't mention anything about this on the call. On another note, would someone clarify what Matt likely meant by delisting would be catastrophic to the operation of the business (or something to that effect). I assumed this meant raising capital at some point in the future by issuing stock but wasn't sure if there were other reasons. I wonder if the Tase is also some how effected if we are delisted from Nasdaq ? anybody ? I would have thought it wouldn't matter. Because I know for example that companies can trade on the Toronto exchange even if delisted from Nasdaq. However, it may be different with the TASE. www.tase.co.il/Eng/Listings/DualListing/Pages/DualListing.aspx"The TASE offers companies traded in the U.S.A. and U.K. an attractive way to dual-list their shares on the TASE. Companies whose shares are traded on the NASDAQ, the New York Stock Exchange (NYSE), the NYSE MKT(formerly AMEX), or the London Stock Exchange (LSE) Main Market can dual-list on the TASE." "The Israel Securities Authority (ISA) can allow companies incorporated abroad to list under the dual-listing procedure." So unless Mannkind is incorporated in Israel, it seems (from language on the TASE site that is admittedly ambiguous) as though it may not qualify for trading there. |
|
